General Information of Drug Therapeutic Target (DTT) (ID: TTIXTO3)

DTT Name Staphylococcus Topoisomerase IV (Stap-coc parC)
Synonyms Topoisomerase IV subunit A; DNA topoisomerase 4 subunit A
Gene Name Stap-coc parC
DTT Type
Successful target
[1]
BioChemical Class
Topoisomerase GyrA ParC
UniProt ID
PARC_STAAS
TTD ID
T40696
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 5.6.2.3
Sequence
MSEIIQDLSLEDVLGDRFGRYSKYIIQERALPDVRDGLKPVQRRILYAMYSSGNTHDKNF
RKSAKTVGDVIGQYHPHGDSSVYEAMVRLSQDWKLRHVLIEMHGNNGSIDNDPPAAMRYT
EAKLSLLAEELLRDINKETVSFIPNYDDTTLEPMVLPSRFPNLLVNGSTGISAGYATDIP
PHNLAEVIQATLKYIDNPDITVNQLMKYIKGPDFPTGGIIQGIDGIKKAYESGKGRIIVR
SKVEEETLRNGRKQLIITEIPYEVNKSSLVKRIDELRADKKVDGIVEVRDETDRTGLRIA
IELKKDVNSESIKNYLYKNSDLQISYNFNMVAISDGRPKLMGIRQIIDSYLNHQIEVVAN
RTKFELDNAEKRMHIVEGLIKALSILDKVIELIRSSKNKRDAKENLIEVYEFTEEQAEAI
VMLQLYRLTNTDIVALEGEHKELEALIKQLRHILDNHDALLNVIKEELNEIKKKFKSERL
SLIEAEIEEIKIDKEVMVPSEEVILSMTRHGYIKRTSIRSFNASGVEDIGLKDGDSLLKH
QEVNTQDTVLVFTNKGRYLFIPVHKLADIRWKELGQHVSQIVPIEEDEVVINVFNEKDFN
TDAFYVFATQNGMIKKSTVPLFKTTRFNKPLIATKVKENDDLISVMRFEKDQLITVITNK
GMSLTYNTSELSDTGLRAAGVKSINLKAEDFVVVTEGVSENDTILMATQRGSLKRISFKI
LQVAKRAQRGITLLKELKKNPHRIVAAHVVTGEHSQYTLYSKSNEEHGLINDIHKSEQYT
NGSFIVDTDDFGEVIDMYIS
Function Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
10 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Besifloxacin DMPHXMI Ocular inflammation 9C61.24 Approved [1]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [2]
Delafloxacin Meglumine DMVTU5Q Acute bacterial skin infection 1C41 Approved [3]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [4]
Gatifloxacin DMSL679 Acute gonococcal cervicitis Approved [2]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [2]
Levofloxacin DMS60RB Acute maxillary sinusitis Approved [2]
Moxifloxacin DMU8V4S Bacterial infection 1A00-1C4Z Approved [2]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [5]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Approved Drug(s)
6 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABT-492 DMJFD2I Bacterial infection 1A00-1C4Z Phase 3 [6]
Nemonaxacin DMIPNBG Methicillin-resistant staphylococci infection 1A00-1A09 Phase 3 [7]
Zabofloxacin DMEY1F3 Pneumonia CA40 Phase 3 [8]
WCK-2349 DMH6XJG MRSA infection 1D01.0Y Phase 2 [9]
WCK-771 DMVQARP Bacterial infection 1A00-1C4Z Phase 2 [10]
WCK-1152 DMJQHTN Respiratory tract inflammation CA07 Phase 1 [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Clinical Trial Drug(s)
4 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Avarofloxacin DMWA957 Bacterial pneumonia CA40.0 Discontinued in Phase 2 [12]
DX-619 DMSTA5L Bacterial infection 1A00-1C4Z Discontinued in Phase 2 [13]
DK-507k DME5PXL Bacterial infection 1A00-1C4Z Discontinued in Phase 1 [14]
CBR-2092 DMJAGKY Bacterial infection 1A00-1C4Z Terminated [15]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
NSFQ-105 DMSLA8X Discovery agent N.A. Investigative [16]
Premafloxacin DMC4W03 Discovery agent N.A. Investigative [17]
------------------------------------------------------------------------------------

References

1 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
6 Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus
7 In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.J Antimicrob Chemother.2009 Dec;64(6):1226-9.
8 DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
9 DOI: 10.1038/ja.2013.86
10 Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models
11 DOI: 10.1093/jac/dki361
12 Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
13 DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother. 2005 Dec;49(12):5051-7.
14 In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone
15 In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.Antimicrob Agents Chemother.2008 Jul;52(7):2313-23.
16 Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target i... Antimicrob Agents Chemother. 2000 Feb;44(2):320-5.
17 Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob Agents Chemother. 2003 Mar;47(3):941-7.